In the most recent trading session, Amgen (AMGN) closed at $270, indicating a +1.33% shift from the previous trading day.

Leerink Partners analyst David Risinger has maintained their neutral stance on AMGN stock, giving a Hold rating yesterday. David Risinger has ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the biotech and pharmaceutical world, FDA approval is the ...

The stock of AMGEN Inc. (AMGN) has gone down by -2.12% for the week, with a -1.24% drop in the past month and a -13.03% drop in the past quarter. The volatility ratio for the week is 1.88%, and the ...

Amgen(NASDAQ: AMGN), a top-tier U.S. biotech firm, has been a coveted dividend stock since it began regular distributions to ...

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

AMGEN INC (AMGN) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation.

AMGEN INC (AMGN) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation.

Amgen has a history of outperforming peers and the market due to its effective capital allocation in the pharmaceutical industry. AMGN is executing well with sales and volume growth, and has a ...

Amgen's stock isn't expensive, but the business does face some challenges, which could have investors thinking twice.

Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close.